CDMO 2087 Views Recipharm continues manufacturing operations in Höganäs Malin Otmani October 26, 2018 Recipharm announces that it will…
Business article 1991 Views Recipharm prepares for Brexit Malin Otmani June 13, 2018 With less than a year…
Business Award 2361 Views Recipharm awarded for growth in France Malin Otmani November 29, 2017 Recipharm has received recognition for…
CDMO 1947 Views Recipharm to end operations in two facilities in Sweden Malin Otmani November 13, 2017 Recipharm has announced that it…
CDMO 1738 Views Recipharm equips Lisbon facility for US and European serialisation Malin Otmani October 24, 2017 Recipharm has equipped its sixth…
CDMO 1654 Views Recipharm and LIDDS establish industrial manufacturing capabilities Malin Otmani August 9, 2017 Recipharm and LIDDS have together…
CDMO 3507 Views Recipharm opens new GMP suite Malin Otmani April 25, 2017 Recipharm has opened a newly…
CDMO 2951 Views Cobra Biologics expands gene therapy manufacturing operations Anneli Hidalgo April 18, 2017 Cobra Biologics has announced the…
CDMO 1923 Views Recipharm manufactures to the Japanese market Malin Otmani March 27, 2017 Recipharm has entered into a…
Acquisition 4282 Views AGC Asahi Glass acquires CMC Biologics Malin Otmani January 3, 2017 Danish CDMO CMC Biologics and…
CDMO 2001 Views Recipharm enters new collaboration Malin Otmani December 5, 2016 Recipharm is entering into a…
CDMO 2042 Views Recipharm invests in its Italian API facility Malin Otmani November 2, 2016 Recipharm has announced an investment…
CDMO 2052 Views Recipharm to open new GLP bioanalysis laboratory in Uppsala Malin Otmani October 19, 2016 Recipharm has announced a 5 million…
Acquisition 1903 Views Recipharm creates global CDMO through new acquisitions Malin Otmani April 16, 2016 Swedish CDMO Recipharm continues to…
Acquisition 2403 Views Recipharm to acquire Mitim Srl for SEK 640 million Malin Otmani February 24, 2016 Recipharm AB announces that it…
CDMO 1616 Views Recipharm makes €40m investment Malin Otmani February 19, 2016 Recipharm will invest €40m over the…